Cytosorbents Corporation’s CTSO share price has dipped by 5.17%, which has investors questioning if this is right time to buy ...

Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Ind ...

Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention ...

CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical ...

Proceedings of the 2022 UAB CRRT Academy: Non-Invasive Hemodynamic Monitoring to Guide Fluid Removal with CRRT and Proliferation of Extracorporeal Blood Purification Devices.

CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval ...

CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval ...

CytoSorb® is a safe and effective extracorporeal cytokine filter, designed to target the prevention or treatment of organ failure which is the cause of nearly half of all deaths in the intensive ...

PRINCETON, N.J., April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (CTSO) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac ...

The initial term of the agreement is three years, and is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity. Mr. Stephen Bailey, Managing Director of L.IN.C., stated ...